AOBI — American Oriental Bioengineering Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.03% | ||
| Return on Equity | -27.88% | ||
| Operating Margin | -66.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 264.64 | 296.15 | 305.94 | 212.69 | 145.1 | n/a | n/a | -2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +23.37 | -30.17 | -63.25 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
American Oriental Bioengineering, Inc. is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Its products in this category include Jinji Series, Cease Enuresis Patch (CE Patch), and Boke Series. Nutraceutical products are intended for the overall well-being. It markets several nutraceutical products in China, which include its soybean peptide based drinks, tablets, powder and instant coffee.
Directors
- Shujun Liu CHM (59)
- Yanchun Li CFO (43)
- Xiaopeng Xu COO (63)
- Yan Gao CAO (40)
- Jun Min VPR (58)
- Cosimo Patti IND (62)
- Xianmin Wang IND (69)
- Baiqing Zhang IND (59)
- Last Annual
- December 31st, 2012
- Last Interim
- September 30th, 2013
- Incorporated
- November 30th, 1970
- Public Since
- December 18th, 2006
- No. of Shareholders
- 393
- No. of Employees
- 3,719
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 58,007
- Address
- 1 Liangshuihe First Avenue, SHENZHEN, 518026
- Web
- Phone
- +86 45186666601
- Auditors
- Weinberg & Company
Similar to AOBI
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:02 UTC, shares in American Oriental Bioengineering are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in American Oriental Bioengineering last closed at $0.00 and the price had moved by +150% over the past 365 days. In terms of relative price strength the American Oriental Bioengineering share price has outperformed the S&P500 Index by +120.57% over the past year.
There is no consensus recommendation for this security.
American Oriental Bioengineering does not currently pay a dividend.
American Oriental Bioengineering does not currently pay a dividend.
American Oriental Bioengineering does not currently pay a dividend.
To buy shares in American Oriental Bioengineering you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in American Oriental Bioengineering had a market capitalisation of .
Here are the trading details for American Oriental Bioengineering:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AOBI
Based on an overall assessment of its quality, value and momentum American Oriental Bioengineering is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like American Oriental Bioengineering. Over the past six months, its share price has outperformed the S&P500 Index by +115.52%.
As of the last closing price of $0.00, shares in American Oriental Bioengineering were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The American Oriental Bioengineering PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
American Oriental Bioengineering's management team is headed by:
- Shujun Liu - CHM
- Yanchun Li - CFO
- Xiaopeng Xu - COO
- Yan Gao - CAO
- Jun Min - VPR
- Cosimo Patti - IND
- Xianmin Wang - IND
- Baiqing Zhang - IND